New FDA requirements could provide opportunities for Genmab, CEO says
Genmab CEO Jan van de Winkel thinks the FDA’s new project, Optimus, could be good for the firm, as it will require more work do be done to find the optimal dosage of cancer treatments.
by marketwire, translated by catherine brett
New guidelines from the US Food and Drug Administration (FDA) concerning the development of cancer treatments could have a big impact on the sector, says Genmab’s CEO Jan van de Winkel.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
CEO van de Winkel wants long tenure at Genmab
For subscribers
FDA requests 34-percent budget increase
For subscribers
Genmab receives orphan drug designation from FDA
For subscribers
.jpg&w=384&q=75)
